What is the true cost of ownership when it comes to medical equipment? When you think of capital spending, ownership costs can become very configurable from the standpoint that everyone has different systems, tools and methods to arrive at a base value. What we at Vizient have done Is to put tools in place that allow for a certain amount of standardization and consistency, essentially leveling the field when It comes to ownership costs and ownership strategies.   Guest: Danny Cisneros Sr. Consulting Director Vizient   Host: Susan Edwards Product Marketing Manager Vizient   Show Notes: [00:46 – 03:15] What Is total cost of ownership? What Is Its history? [03:15 – 04:13] The science behind "unbundling" of equipment costs [04:13 – 08:20] How does the cost of ownership Impact expansion? [08:20 – 10:22] The approach to consolidating people and resources [10:22 – 12:28] Unbundling and the lifecycle of equipment [12:28 – 13:44] Finding the hidden costs and working over time [13:44 – 15:27] Assets advice for organizations [15:27 – 16:22] Balancing needs and outcomes for the ASC's [16:22 – 19:07] Real life examples and how to respond [19:07 – 21:15] Does everyone face the same challenges and what Is It about capital equipment that adds to the complexity of the Issue? [21:15 – 22:12] Terminology [22:12 – 23:44] Wrap up and suggestions   Links | Resources: CES Case Studies   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed

Whether you're navigating decentralized purchasing, benchmarking spend, or trying to align capital budget system wide, the Capital Spend Insights tool was built to transform how your organization approaches capital planning. Mike Kolp, associate principal from Vizient's Capital Equipment Solutions team joins host Susan Edwards to share how health systems are using Capital Spend Insights to unlock smarter, faster and more strategic decisions.   Guests: Mike Kolp,  Associate Principal, Vizient Capital Equipment Solutions Vizient   Moderator: Susan Edwards Marketing Communications Manager   Show Notes: [01:09 – 02:04]  The why behind Capital Spin Insights [02:05 – 03:15]  Industry overarching trends needing solutions for capital provurement [03:16 – 03:59]  How capital spend insights tool changes visibility traditionally exposed in the capital procurement process [04:00 – 05:11]  How Capital Spend Insights make the quote review process better [05:12 – 07:37]  Comparing Capital Spend Insights to what's available in the marketplace from other competitors [07:38 – 10:22]  How Capital Spend Insights works alongside or in tandem with the other Vizient data solutions [10:45 – 11:36]  How full fledged subscribers are they using the tool most effectively in their organizations today [11:37 – 13:00]  Common types of projects that got clients interested in using this tool [13:01 – 17:09]  The tool’s GPO compliance component and the pull through of budget alignments [17:10 – 19:03]  New improvements and enhancements for the solution [19:04 – 20:41]  Comparing Capital Spend Insights to key Competitors [20:42 – 23:25]  Key Takaways [23:26 – 24:19]  Next steps for people interested in the tool [24:20 – 25:08]  Mike will be talking about the tool at the Vizient Summit   Links | Resources: Link to Capital Equipment Solutions webpage: Click here Link to Capital Spend Insights video: Click here Capital Spend Insights fact sheet: Click here   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed

Theranostics is a groundbreaking topic that's reshaping how we diagnose and treat cancer. It's a cutting-edge approach in cancer care, combining diagnosing and treating cancer using the same molecular tools. Theranostics has the spotlight because it's delivering on a promise we've been chasing for years in cancer care, truly personalized targeted treatment with fewer side effects than traditional options.   Guests: Lindsay Williams, MBA, CNMT, R.T.(N)(CT)(ARRT) Pharmacy Sourcing Portfolio Executive Vizient   Setu Shah, MPH Sr. Associate, Intelligence Sg2   Janna Laton, MBA, CNMT, NMTCB(CT), R.T.(R)(N)(MR)(ARRT) Independent Contributor and SME   Host: Adam Fairbourn, MBA, CNMT Senior Director, Contract Services Vizient, Capital Equipment Solutions   Show Notes: [00:48 – 01:55] What it takes for a healthcare organization to implement Theranostics [01:56 – 04:04] Success stories solving for some of the access and workflow issues [04:05 – 05:11] Education and training programs needed to support demand for nuclear medicine specialists and technologists [05:12 – 07:54] What's driving that growth in the field [07:55 – 09:34] What’s most exciting about theranostics over the next five to 10 years [09:34– 10:08] Will Theranostics become the standard of care for more types of cancer than we see today [10:09 – 11:30] The future of cancer care and Theranostics [11:30– 12:03] What Vizient is doing on the Theranostics front   Links | Resources: Vizient article - https://www.vizientinc.com/insights/diagnostic-imaging Sg2 Perspectives Podcast: Transforming Cancer Care Delivery Sg2 Perspectives Podcast: Cell and Gene Therapy in Practice   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed

Theranostics is a groundbreaking topic that's reshaping how we diagnose and treat cancer. It's a cutting-edge approach in cancer care, combining diagnosing and treating cancer using the same molecular tools. Theranostics has the spotlight because it's delivering on a promise we've been chasing for years in cancer care, truly personalized targeted treatment with fewer side effects than traditional options.   Guests: Lindsay Williams, MBA, CNMT, R.T.(N)(CT)(ARRT) Pharmacy Sourcing Portfolio Executive Vizient   Setu Shah, MPH Sr. Associate, Intelligence Sg2   Janna Laton, MBA, CNMT, NMTCB(CT), R.T.(R)(N)(MR)(ARRT) Independent Contributor and SME   Host: Adam Fairbourn, MBA, CNMT Senior Director, Contract Services Vizient, Capital Equipment Solutions   Show Notes: [00:45] Defining Theranostics and why it’s getting attention [02:10] “See what you treat and treat what you see” captures the power of Theranostics [03:10] Why neuroendocrine tumors and prostate cancer are particularly well suited for this approach [03:50] Prostate specific membrane antigen or PSMA targeted imaging and treatment work and results [05:28] How Theranostics compares with more traditional cancer treatments in terms of precision and side effects   Links | Resources: Vizient article - https://www.vizientinc.com/insights/diagnostic-imaging Sg2 Perspectives Podcast: Transforming Cancer Care Delivery Sg2 Perspectives Podcast: Cell and Gene Therapy in Practice   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed

This episode highlights the mainstay of Vizient’s group purchasing strategy – the Group Buy Program. Celebrating 20 years of delivering value, the Group Buy Program is a flexible, time-bound program for healthcare organizations that enables them to achieve enhanced savings, better terms and product upgrades while leveraging their GPO participation.   Guests: Rebecca Gayden Senior Principal, Capital Equipment Solutions Vizient   Tammi Pegues Program Services Director, Group Buys Vizient   Host: Susan Edwards Marketing Communications Manager Vizient   Show Notes: [01:00-2:28] Origins of the Group Buy Program [02:29-04:29] How the program has evolved [04:30-05:23] Quarterly inspiration to put deals together [05:24-06:48] Variety and flexibility – no commitment required, advanced planning capability, value from group buys [07:15-08:23] Two decades of growth   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed

On this episode, we finish our discussion on the dynamic growth and future of diagnostic imaging. Imaging is expanding well beyond the hospital walls and factors into any strategic plans for the future.   Guests: Gurmeet Bawa, MS Consulting Director Sg2 Intelligence Vizient   Adam Fairbourn, MBA Director, Contract Services Capital Equipment Solutions Vizient   Host: Andrew Rebhan, MHIHIM Senior Consulting Director Sg2 Intelligence Vizient   Show Notes: [00:58-02:02] Sustainability and imaging [02:03-03:17] A new energy efficiency [03:18-06:12] Promising strategies for workforce challenges [06:13-09:11] AI innovation and adoption [09:12-12:57] Mobile imaging technologies and reaching more patients [12:58-14:51] Capital planning and equity [14:52-16:24] Advocacy efforts to keep an eye on [16:25-17:50] Looking ahead to exciting future   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed

Diagnostic imaging is a dynamic growth engine in healthcare, reaching into areas such as AI, sustainability and emerging therapies with tremendous improvements now and in the near future. Its reach goes well beyond the hospital walls. On the next two episodes, our guests examine where diagnostic imaging is today and the forces determining its future.   Guests: Gurmeet Bawa, MS Consulting Director Sg2 Intelligence Vizient   Adam Fairbourn, MBA Director, Contract Services Capital Equipment Solutions Vizient   Host: Andrew Rebhan, MHIHIM Senior Consulting Director Sg2 Intelligence Vizient   Show Notes: [01:10-02:20] Primary forces driving growth in diagnostic imaging [02:21-03:37] Imaging’s importance to the growth of a health system [03:38-05:30] Changing strategies involving imaging [05:31-06:47] Infrastructure and equipment trends [06:48-07:58] Rising and widespread demand [07:59-08:58] Precision is key [09:00-09:54] Challenges ahead   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed

Chart your course with The Capital Compass, an exciting new podcast to help you navigate your journey to value. On The Capital Compass, we explore today's most dynamic areas in capital spend strategy. From imaging and Group Buys, we dive into the emerging trends and market drivers that are shaping the big decisions for capital procurement. As a part of the powerful lineup of Vizient podcasts, The Capital Compass is available on all your favorite podcast channels.   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed